Ibandronate sodium monohydrate | CAS#138926-19-9 | osteoporosis treatment

MedKoo Cat#: 540214 | Name: Ibandronate sodium monohydrate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ibandronate sodium, also known as Ibandronate sodium monohydrate, is used to treat osteoporosis. It increases bone mineral density, prevents resorption, and decreases osteoclast activity. It may inhibit angiogenesis.

Chemical Structure

Ibandronate sodium monohydrate

CAS#138926-19-9

Theoretical Analysis

MedKoo Cat#: 540214

Name: Ibandronate sodium monohydrate

CAS#: 138926-19-9

Chemical Formula: C9H24NNaO8P2

Exact Mass:

Molecular Weight: 357.26

Elemental Analysis: C, 30.09; H, 6.73; N, 3.90; Na, 6.40; O, 35.63; P, 17.24

Price and Availability

Size	Price	Availability
1g	USD 250.00	2 Weeks
2g	USD 400.00	2 Weeks
5g	USD 650.00	2 Weeks
10g	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Boniva; Ibandronate sodium; Ibandronate sodium monohydrate; Sodium trihydrogen (1-hydroxy-3-(methylpentylamino)propylidene)diphosphonate, monohydrate

IUPAC/Chemical Name

sodium hydrogen (1-hydroxy-3-(methyl(pentyl)amino)-1-phosphonopropyl)phosphonate hydrate

InChi Key

VBDRTGFACFYFCT-UHFFFAOYSA-M

InChi Code

InChI=1S/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1

SMILES Code

CCCCCN(CCC(P([O-])(O)=O)(P(O)(O)=O)O)C.[H]O[H].[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Ibandronate Sodium Monohydrate is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.

In vitro activity:

In lines with western blot, the results of autophagy flux and TEM assay further confirmed that autophagy, occurred in Ang II + IBAN group, was higher than that in the untreated and Ang II or IBAN-treated groups (Fig. 2B, C). Therefore, these findings demonstrated that IBAN promoted autophagy in Ang II-treated HUVECs and human pulmonary microvascular endothelial cells (HPMECs). Reference: Cell Death Discov. 2022 Apr 9;8(1):186. https://pubmed.ncbi.nlm.nih.gov/35397636/

In vivo activity:

Administration of IBN (ibandronate) at 1 μg/kg (IBN_1) was insufficient for the suppression of bone loss and morphological change in trabeculae; however, administration of 3 μg/kg (IBN_3) and 10 μg/kg (IBN_10) significantly suppressed the osteoporotic changes induced by estrogen deficiency. Reference: Calcif Tissue Int. 2022 Jun;110(6):736-745. https://pubmed.ncbi.nlm.nih.gov/34989822/

	Solvent	mg/mL	mM
Solubility
	PBS (pH 7.2)	0.3	0.70
	Water	48.5	135.76

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 357.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Han J, Yang J, Wang Q, Yin X, Sun Z, Huang C, Chen G, Zheng L, Jiang D. Ibandronate promotes autophagy by inhibiting Rac1-mTOR signaling pathway in vitro and in vivo. Cell Death Discov. 2022 Apr 9;8(1):186. doi: 10.1038/s41420-022-00995-6. PMID: 35397636; PMCID: PMC8994753. 2. Lotz EM, Cohen DJ, Ellis RA, Wayne JS, Schwartz Z, Boyan BD. Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis. JBMR Plus. 2019 Mar 6;3(7):e10184. doi: 10.1002/jbm4.10184. PMID: 31372590; PMCID: PMC6659452. 3. Ishimoto T, Saito M, Ozasa R, Matsumoto Y, Nakano T. Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae. Calcif Tissue Int. 2022 Jun;110(6):736-745. doi: 10.1007/s00223-021-00940-2. Epub 2022 Jan 6. PMID: 34989822; PMCID: PMC9108105. 4. Takeda S, Sakai S, Tanaka K, Tomizawa H, Serizawa K, Yogo K, Urayama K, Hashimoto J, Endo K, Matsumoto Y. Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats. Calcif Tissue Int. 2017 Jul;101(1):65-74. doi: 10.1007/s00223-017-0255-6. Epub 2017 Feb 28. PMID: 28246925; PMCID: PMC5486915.

In vitro protocol:

In vivo protocol:

1. Ishimoto T, Saito M, Ozasa R, Matsumoto Y, Nakano T. Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae. Calcif Tissue Int. 2022 Jun;110(6):736-745. doi: 10.1007/s00223-021-00940-2. Epub 2022 Jan 6. PMID: 34989822; PMCID: PMC9108105. 2. Takeda S, Sakai S, Tanaka K, Tomizawa H, Serizawa K, Yogo K, Urayama K, Hashimoto J, Endo K, Matsumoto Y. Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats. Calcif Tissue Int. 2017 Jul;101(1):65-74. doi: 10.1007/s00223-017-0255-6. Epub 2017 Feb 28. PMID: 28246925; PMCID: PMC5486915.

1: Wahl O, Holzgrabe U. Impurity profiling of ibandronate sodium by HPLC-CAD. J Pharm Biomed Anal. 2015 Oct 10;114:254-64. doi: 10.1016/j.jpba.2015.06.002. Epub 2015 Jun 6. PubMed PMID: 26092222. 2: Zhang W, Yang DL, Wang YX, Wang HW, Zhen ZJ, Zhang YZ, Shen Y. In vitro osteoclast-suppressing effect of sodium ibandronate. Chin Med J (Engl). 2013 Feb;126(4):751-5. PubMed PMID: 23422201. 3: Wu SN, Huang YM, Liao YK. Effects of ibandronate sodium, a nitrogen-containing bisphosphonate, on intermediate-conductance calcium-activated potassium channels in osteoclast precursor cells (RAW 264.7). J Membr Biol. 2015 Feb;248(1):103-15. doi: 10.1007/s00232-014-9747-8. Epub 2014 Nov 2. PubMed PMID: 25362532. 4: Tobinai M. [Ibandronate]. Clin Calcium. 2011 Jan;21(1):79-86. doi: CliCa11017986. Review. Japanese. PubMed PMID: 21187598. 5: Recknor C, Czerwinski E, Bone HG, Bonnick SL, Binkley N, Palacios S, Moffett A, Siddhanti S, Ferreira I, Ghelani P, Wagman RB, Hall JW, Bolognese MA, Benhamou CL. Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial. Obstet Gynecol. 2013 Jun;121(6):1291-9. doi: 10.1097/AOG.0b013e318291718c. PubMed PMID: 23812464. 6: Ma Z, Li Y, Zhou M, Huang K, Hu H, Liu X, Xu X. Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis. PLoS One. 2016 Mar 1;11(3):e0150203. doi: 10.1371/journal.pone.0150203. eCollection 2016. PubMed PMID: 26930292; PubMed Central PMCID: PMC4773099. 7: Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H; MOVER Study Group. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int. 2013 Aug;93(2):137-46. doi: 10.1007/s00223-013-9734-6. Epub 2013 May 5. PubMed PMID: 23644930; PubMed Central PMCID: PMC3717162. 8: Rossini M, Orsolini G, Adami S, Kunnathully V, Gatti D. Osteoporosis treatment: why ibandronic acid? Expert Opin Pharmacother. 2013 Jul;14(10):1371-81. doi: 10.1517/14656566.2013.795949. Epub 2013 May 7. Review. PubMed PMID: 23650954. 9: Alvarez GS, Echazu MI, Olivetti CE, Desimone MF. Synthesis and characterization of ibandronate-loaded silica nanoparticles and collagen nanocomposites. Curr Pharm Biotechnol. 2015;16(7):661-7. PubMed PMID: 25934976. 10: Hou Y, Gu K, Xu C, Ding H, Liu C, Tuoheti Y. Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis. Medicine (Baltimore). 2015 Jul;94(26):e1007. doi: 10.1097/MD.0000000000001007. Review. PubMed PMID: 26131800; PubMed Central PMCID: PMC4504649. 11: Keating GM. Ibandronate: A Review in Japanese Patients with Osteoporosis. Drugs Aging. 2016 Apr;33(4):295-303. doi: 10.1007/s40266-016-0360-7. Review. PubMed PMID: 26915075. 12: Bergner R, Siegrist B, Gretz N, Pohlmeyer-Esch G, Kränzlin B. Nephrotoxicity of ibandronate and zoledronate in Wistar rats with normal renal function and after unilateral nephrectomy. Pharmacol Res. 2015 Sep;99:16-22. doi: 10.1016/j.phrs.2015.04.016. Epub 2015 May 11. PubMed PMID: 25976681. 13: Park JW, Hwang SR, Jeon OC, Moon HT, Byun Y. Enhanced oral absorption of ibandronate via complex formation with bile acid derivative. J Pharm Sci. 2013 Feb;102(2):341-6. doi: 10.1002/jps.23413. Epub 2012 Dec 11. PubMed PMID: 23233267. 14: Chung YS, Kang HC, Lee T. Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model. Yonsei Med J. 2015 Nov;56(6):1643-50. doi: 10.3349/ymj.2015.56.6.1643. PubMed PMID: 26446649; PubMed Central PMCID: PMC4630055. 15: Tariq S, Tariq S, Alam SS, Baig M. Effect of ibandronate therapy on serum homocysteine and leptin in postmenopausal osteoporotic females. Osteoporos Int. 2015 Mar;26(3):1187-92. doi: 10.1007/s00198-014-2909-9. Epub 2014 Oct 2. PubMed PMID: 25274281. 16: Chapurlat RD, Laroche M, Thomas T, Rouanet S, Delmas PD, de Vernejoul MC. Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial. Osteoporos Int. 2013 Jan;24(1):311-20. doi: 10.1007/s00198-012-1947-4. Epub 2012 Mar 9. PubMed PMID: 22402673. 17: Kumar MN, Kumar KS, Kumar VJ, Prasanna SJ, Sharma HK, Reddy VK. Stability indicating ion chromatography method for the simultaneous determination of ibandronate sodium drug substance and its impurities. J Pharm Biomed Anal. 2011 Feb 20;54(3):596-601. doi: 10.1016/j.jpba.2010.09.026. Epub 2010 Sep 29. PubMed PMID: 20952141. 18: Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. Osteoporos Int. 2012 Jun;23(6):1747-56. doi: 10.1007/s00198-011-1773-0. Epub 2011 Sep 28. PubMed PMID: 21953471. 19: Bala Y, Kohles J, Recker RR, Boivin G. Oral ibandronate in postmenopausal osteoporotic women alters micromechanical properties independently of changes in mineralization. Calcif Tissue Int. 2013 Jan;92(1):6-14. doi: 10.1007/s00223-012-9658-6. Epub 2012 Oct 23. PubMed PMID: 23090678. 20: Vitor S, Nunes A, Fonseca C, Freitas J. Ibandronate-associated ischemic colitis: case report. Acta Reumatol Port. 2012 Oct-Dec;37(4):342-4. PubMed PMID: 24126426.